A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis

Clinical trial NCT04711148 · UNKNOWN

Trial details

NCT number: NCT04711148
Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Relapsing Remitting Multiple Sclerosis

Start date: 2021-03-01
Primary completion: 2026-02-25
Enrollment: 160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.